Nvidia-backed Iambic Therapeutics files for Nasdaq IPO

By Splitfeed EditorialLast updated Sep 26, 2026, 20:18 UTC

Iambic Therapeutics, an AI-driven drug discovery company, filed for a US IPO on September 21, 2026, targeting a Nasdaq listing under the ticker symbol "IAM". The filing confirmed that Nvidia holds 9.6 million shares in the company ahead of the listing, and that the Qatar Investment Authority is also among its named backers. Endpoints News reported that the filing disclosed new details around clinical trials and dealmaking activity, though the company recorded losses of approximately one billion dollars in the six months leading up to the filing.

The IPO lands at a moment when AI-assisted drug discovery has drawn sustained investor interest, with large technology and sovereign wealth players taking positions alongside traditional biotech investors. The sheer scale of the pre-IPO losses raises a question that the filing itself cannot answer: whether the backing of a name like Nvidia, whose 9.6 million shares give the listing a degree of credibility by association, is enough to sustain appetite once public market investors examine the financials closely. The clinical and dealmaking disclosures noted by Endpoints News may prove equally important, since they give analysts something concrete to evaluate beyond the company's AI credentials.

No published reactions have come yet from the Pro-AI or Anti-AI camps. Typically, Pro-AI voices would frame the Nvidia stake and the AI-first research model as validation that machine learning is moving from experiment to commercial-stage medicine, while Anti-AI voices would point to the billion-dollar loss figure as evidence that AI drug development remains expensive and unproven relative to its promises. The Middle Ground camp, represented here by AI Health Hub on Bluesky, put the tension plainly: the IPO will test whether Wall Street prices AI biotechs on clinical results or on technology hype, a distinction that has not yet been forced in the private markets where much of this sector has lived.

The IPO pricing date and the initial trading session for "IAM" on Nasdaq will be the first concrete signals of how public investors weigh those competing considerations. Any updated clinical data released in connection with the roadshow would add further information to that judgment.